ArticleBMC cardiovascular disorders2026
Percutaneous mitral balloon commissurotomy in juvenile rheumatic mitral stenosis patients: a ten-year experience from Ethiopia.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic heart disease (RHD) remains a major cause of acquired valvular heart disease in low- and middle-income countries, disproportionately affecting young people. The mitral valve is most frequently involved, and severe rheumatic mitral stenosis (MS) represents the dominant presentation. MS is a progressive disease that gradually impairs cardiac output and, if untreated, leads to pulmonary hypertension, right-sided heart failure, and premature death. Percutaneous mitral balloon commissurotomy (PMBC) is considered the first-line intervention for symptomatic severe MS with favorable valve anatomy. This study aimed to assess the clinical, echocardiographic, and procedural outcomes of PMBC among juvenile patients with rheumatic MS in Ethiopia.
methodsA Descriptive cross-sectional study was conducted at the Cardiac Center Ethiopia, Addis Ababa, from July to August 2025. All consecutive patients who underwent PMBC during the study period and fulfilled eligibility criteria were included (n = 86). Data were analyzed using STATA 17. Continuous variables were expressed as means ± SD or medians (IQR), and categorical variables as frequencies and percentages. Pre- and post-procedure echocardiographic and clinical parameters were compared using paired statistical tests. Associations between baseline characteristics and immediate outcomes were examined using Fisher’s exact tests.
resultsThe median age was 15 years (± 5), and 60.5% (n = 52) were female. Patients originated from multiple Ethiopian regions, predominantly Amhara 28 (32.6%) and Oromia 25 (29.1%), with 65.06% residing in Rural areas. Severe MS accounted for 84 (97.7%) of cases, while 2 patients (2.3%) presented with severe restenosis. 82 (95.4%) had a mitral valve score ≤ 8. The mitral valve area increased significantly from 0.6 cm² (IQR: 0.26) to 1.5 cm² (IQR: 0.6), and the mean mitral gradient decreased from 31.4 ± 8.3 mmHg to 16.4 ± 5.6 mmHg (both p < 0.001). Procedural success was achieved in 85 cases (98.84%).
conclusionPMBC in juvenile patients with severe rheumatic MS in Ethiopia is a safe and effective intervention, demonstrating significant improvements in mitral valve area and mean mitral gradient, with a high procedural success rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.